<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127773">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01932775</url>
  </required_header>
  <id_info>
    <org_study_id>ClinDiab-04</org_study_id>
    <nct_id>NCT01932775</nct_id>
  </id_info>
  <brief_title>Efficacy, Usability Study of the GlucoTab System for Glycaemic Management in Type 2 Diabetic Patients at General Wards</brief_title>
  <official_title>An Open, Single-centre, Non-controlled Study of Efficacy, Safety and Usability of the GlucoTab System for Glycaemic Management in Non-critically Ill Patients With Type 2 Diabetes at General Wards</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <authority>Austria: Agency for Health and Food Safety</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: To investigate the performance (safety) of the GlucoTab system for glycaemic
      management in non-critically ill patients with type 2 diabetes at general wards.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean percentage of blood glucose measurements in the target range 70 to 140 mg/dl, as calculated by all premeal and bedtime glucose values measured ≥ 24 hours after start of therapy</measure>
    <time_frame>duration of hospital stay (maximum three weeks)</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of blood glucose measurements per day</measure>
    <time_frame>duration of hospital stay (maximum three weeks)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to the insulin dose suggestion of the GlucoTab system</measure>
    <time_frame>duration of hospital stay (maximum three weeks)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean daily blood glucose as calculated by premeal and bedtime blood glucose values: Overall and per treatment day</measure>
    <time_frame>duration of hospital stay (maximum three weeks)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>GlucoTab System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GlucoTab System</intervention_name>
    <arm_group_label>GlucoTab System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent obtained after being advised of the nature of the study

          -  Male or female aged ≥18 years

          -  Type 2 diabetes (treated with diet, oral agents, non-insulin injected anti-diabetic
             medicine, insulin therapy or any combination of the four) or newly diagnosed
             hyperglycaemia which requires s.c. insulin therapy

        Exclusion Criteria:

          -  Type 1 diabetes, gestational diabetes

          -  Any disease or condition which the investigator or treating physician feels would
             interfere with the trial or the safety of the patient

          -  Pregnancy

          -  Any mental condition rendering the patient incapable of giving his consent

          -  Known or suspected allergy to insulin glargine or insulin aspart

          -  Continuous parenteral nutrition

          -  Participation in another trial which can influence the software algorithm
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas R Pieber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz, Department of Internal Medicine, Division of Endocrinology and Metabolism</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 20, 2014</lastchanged_date>
  <firstreceived_date>August 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
